reports
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1...
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 1 trial in atopic dermatitis and potential expansion into other immune and inflammatory diseases Highlights ITK inhibition novel mechanism of action affecting T cell receptor signaling and T cell differentiation Presented in an oral session at the 67th A...
Sensient Technologies Corp: 1 director
A director at Sensient Technologies Corp sold 4,518 shares at 94.809USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Creative Realities Announces Addition of Tamra Koshewa as CFO
Creative Realities Announces Addition of Tamra Koshewa as CFO Industry Veteran with 30 Years of Financial Acumen to Oversee Next Phase of Expansion LOUISVILLE, Ky, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage, media and AdTech solutions, today announced that it has hired Tamra Koshewa as its new Chief Financial Officer (“CFO”) effective December 1, 2025. Ms. Koshewa is an accomplished finance executive with 30 years of experience across diverse industries including manufac...
The Metals Company Announces Third Quarter 2025 Corporate Update
The Metals Company Announces Third Quarter 2025 Corporate Update NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or the “Company”), a leading developer of the world’s largest resource of critical metals essential to energy, defense, manufacturing and infrastructure, today provided a corporate update and third quarter results for the period ending September 30, 2025. Q3 2025 Financial Highlights Total cash of approximately $115.6 million at September 30, 2025$11.5 million cash used in operations for the quarter ended September 30, 2025Operatin...
Creative Realities Reports Fiscal 2025 Third Quarter Results
Creative Realities Reports Fiscal 2025 Third Quarter Results Transformational Acquisition Sets Stage for Strong Growth Going Forward LOUISVILLE, Ky., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage, media and AdTech solutions, today announced its financial results for the fiscal third quarter ended September 30, 2025. Highlights: Third quarter revenue of $10.5 million versus $14.4 million in the prior-year periodGross profit of $4.8 million for the three months ended Septem...
Creative Realities Announces Addition of Dan McAllister as CRO
Creative Realities Announces Addition of Dan McAllister as CRO Brings Over 25 Years of Experience Transforming Organizations for Rapid Growth LOUISVILLE, Ky., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage, media and AdTech solutions, today announced that it has hired Dan McAllister as Chief Revenue Officer (“CRO”) effective November 17, 2025. Mr. McAllister is a veteran revenue and transformation leader with more than 25 years of experience driving growth across digital sig...
Creative Realities Closes Acquisition of Cineplex Digital Media
Creative Realities Closes Acquisition of Cineplex Digital Media Three Directors Added to Company’s Board LOUISVILLE, Ky., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage, media and AdTech solutions, today announced that it has completed the previously-announced acquisition of Cineplex Digital Media (“CDM”) for CAD $70 million in cash. Included in the transaction is Canada’s largest mall retail media network, a Digital Out-of-Home (DOOH) network of over 750 screens with exclus...
The Metals Company Announces Third Quarter 2025 Corporate Update Confe...
The Metals Company Announces Third Quarter 2025 Corporate Update Conference Call for Thursday, November 13, 2025 NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or the “Company”), a leading developer of the world’s largest estimated undeveloped resource of critical metals essential to energy, defense, manufacturing and infrastructure, today announced that it will host a conference call on Thursday, November 13, 2025, to provide an update on third quarter 2025 financial results and recent corporate developments. Third Quarter 2025 Conference C...
Creative Realities to Participate in Upcoming Craig-Hallum Conference
Creative Realities to Participate in Upcoming Craig-Hallum Conference LOUISVILLE, Ky., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage and media solutions, today announced that it will participate in the 16th Annual Craig-Hallum Alpha Select Conference at the Sheraton NY Times Square Hotel on Tuesday, November 18. The day will consist of one-on-one meetings with management, and institutional investors can contact Craig-Hallum directly to set up time with the Company. About Cre...
Corvus Pharmaceuticals Provides Business Update and Reports Third Quar...
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results Completed enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period) with data announcement anticipated in January Soquelitinib atopic dermatitis phase 2 trial on track to initiate in early Q1 2026 Phase 3 registrational clinical trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open; final Phase 1/1b results accepted for oral presentation at the American Societ...
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1...
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma will be presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place December 6-9, 2025 in Orlando, F...
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthc...
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is being held in Boston, MA. The fireside chat will be on Monday, November 10, 2025 at 8:30 am ET. A webcast of the fireside cha...
Creative Realities, Inc. Announces Third Quarter 2025 Earnings Release...
Creative Realities, Inc. Announces Third Quarter 2025 Earnings Release Date and Conference Call Information LOUISVILLE, Ky., Oct. 31, 2025 (GLOBE NEWSWIRE) -- ("Creative Realities," "CRI," or the "Company") (NASDAQ: ), a leading provider of digital signage and media solutions, announced today that it will release its financial results for the three months ended September 30, 2025 before the market open on Wednesday, November 12, 2025. A conference call to review the results is scheduled for Wednesday, November 12, 2025, at 9:00 am Eastern Time, which will include prepared remarks and mat...
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 20...
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 4, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1...
Creative Realities Wins 2025 DIZZIE Award for Digital Transformation a...
Creative Realities Wins 2025 DIZZIE Award for Digital Transformation at Rogers Arena Award honors CRI’s innovation in redefining the live venue experience through integrated digital design and fan engagement LOUISVILLE, Ky., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (NASDAQ: CREX), a leading provider of digital signage and media solutions, today announced it has won the 2025 Digital Signage Experience (DIZZIE) Award in the Venues category for its Digital Transformation at Rogers Arena project in Vancouver, British Columbia. The recognition celebrates Creative Realities’...
Corvus Pharmaceuticals Announces Presentation of Interim Data from the...
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025 Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows triplet therapy with ciforadenant, ipilimumab and nivolumab is feasible and well tolerated; longer follow-up with patients still on therapy needed to determine potential bene...
Creative Realities Announces Transformational Acquisition
Creative Realities Announces Transformational Acquisition Purchase of Cineplex Digital Media Doubles Size of the Company, Expands North American Footprint, and Brings Significant Synergies; Investor Update Call Scheduled for 11:00AM EST Today LOUISVILLE, Ky., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage, media and AdTech solutions, today announced that it has entered into a share purchase agreement to acquire Cineplex Digital Media (“CDM”), an indirect wholly-owned subsidi...
CRI Named Finalist for the Digital Signage Experience Awards 2025
CRI Named Finalist for the Digital Signage Experience Awards 2025 Company to Compete in the Venues Category with its Implementation at Rogers Arena LOUISVILLE, Ky., Oct. 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), a leading provider of digital signage and media solutions, announced it has been named a finalist in the Venues category of the 2025 Awards, also known as the . The nomination recognizes CRI’s “Digital Transformation at Rogers Arena” project, which elevated fan engagement, streamlined operations, and unlocked new revenue opportunities through state-of-the-art digital signage. ...
Corvus Pharmaceuticals Appoints David Moore to Board of Directors
Corvus Pharmaceuticals Appoints David Moore to Board of Directors SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., has been appointed to the company’s Board of Directors. Mr. Moore brings a wealth of experience from his 27-year career in the industry, including broad expertise across strategy, commercial, market access, business development and investing from ...
Creative Realities Denies Patent Infringement and Vows Resolute Defens...
Creative Realities Denies Patent Infringement and Vows Resolute Defense LOUISVILLE, Ky., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (NASDAQ: CREX) (the “Company” or “CRI”), a leading provider of digital signage, media and AdTech solutions, announced today that it will vigorously defend itself against accusations of patent infringement alleged in a lawsuit filed in Texas federal court by Alpha Modus, Corp., a subsidiary of Alpha Modus Holdings Inc. (AMOD). The lawsuit alleges, in essence, that CRI’s digital signage solutions infringe on AMOD’s patented technologies for rea...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.